877 articles · page 71 of 74
Written by Peter Heuser, Schwabe Williamson & Wyatt In Nichia the Circuit affirms the denial of a permanent injunction because Nichia failed to prove irreparable injury. In RecogniCorp the panel throws out as not being directed to patentable subject matter…
Written by Scott Siera, Ph.D . and Eric Furman, Ph.D. The sale of a product prior to filing a patent application, or “on-sale bar,” has long been a potential barrier to obtaining a patent in the United States. Especially in the biotechnology…
In Pfaff v. Wells Electronics, 525 US 55 (1988), the Supreme Court attempted to focus the factors invoking the on-sale bar of s . 102, by holding that the claimed invention must both be the subject of a “commercial sale”(including offers for…
The difference between "i.e." (id est, "that is") and "e.g." (exempli gratia, "for example") comes up in patent cases from time to time. While the difference is not always clear to some practitioners, it is clear to…
In Phil-Insul , collateral estoppel precludes IntegraSpec from ‎relitigating claim construction in a ‎second case involving a ‎different defendant, different claims and “somewhat” ‎different accused ‎products. In Rembrandt…
In a non-precedential opinion in Ali v. Carnegie Institution of Washington, [2016-2320] (April 12, 2017), the Federal Circuit affirmed the dismissal, on grounds of sovereign immunity, of Ali’s lawsuit to be added as a co-inventor on several of…
Last week Docket Navigator delivered a troubling headline regarding a recent District Court decision – “ Invalidity Opinion Delivered After Product Launch No Defense to Willful Infringement. ” As a practitioner who regularly drafts…
Written by Peter Heuser, Schwabe Williamson & Wyatt In Chudik the Circuit rules that no substantial evidence supports the Board’s determination of ‎anticipation since the ruling is based on a significant and impermissible modification of the…
Written by Rebecca L. Wright , Ph.D. and Eric Furman , Ph.D. In an ongoing set of disputes in Oregon between farmers and corporations that hold GMO patents, farmers may be given a new tool. Oregon House Bill 2739[1] “allows a cause of action against…
Written by Eric Y. Zhou and Vlad Teplitskiy Nearly 40 years ago, the Supreme Court held in Diamond v. Diehr that while patent claims directed solely to abstract ideas, such as mathematical formulas, are not patent eligible, a claim containing a…
In Thales Visionix, Inc., v. U.S., [2015-5150] (March 8, 2017), the Federal Circuit reversed the U.S. Court of Federal Claims (“Claims Court”) determination that the claims of U.S. Patent No. 6,474,159 were directed to patent ineligible subject…
Last month, the Federal Circuit issued its opinion in Shire Development v. Watson Pharmaceuticals, finding that Watson’s generic version of LIALDA® did not infringe U.S. patent 6,773,720 (“the ‘720 patent”). In particular, the…
